Boston Omaha (NYSE:BOC) Azioni

Boston Omaha

Boston Omaha Corp is a us-based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. They generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

Boston Omaha Corporation Class A Common Stock

Boston Omaha Corp

Blue Ocean Acquisition Corp Ordinary Shares - Class A

Blue Ocean Acquisition Corp

Blue Ocean Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Blue Ocean Acquisition Corp Warrants (02/12/2026)

BOUGAINVILLE COPPER ORD by Bougainville Copper Ltd.

Bougainville Copper Ltd

Innovator U.S. Equity Buffer ETF - October

Jefferies analyst Andy Barish upgrades Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) from Underperform to Hold and raises the price target from $165 to $210.

News

Upgrades

Price Target

Analyst Ratings

Jefferies Upgrades Darden Restaurants to Hold, Raises Price Target to $210

-- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction --
-- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction –
-- Well-Tolerated with a Favorable Safety Profile --
-- All Patients Remain on Navenibart --
-- Long-Term Data are Highly Consistent with Previous Results and Support the Potential Market-Leading Profile of Navenibart, Administered 2 or 4 Times Per Year --
-- Phase 3 ALPHA-ORBIT Trial Underway and Enrolling Patients --
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.astriatx.com&amp;esheet=54273873&amp;newsitemid=20250613335891&amp;lan=en-US&amp;anchor=Astria+Therapeutics%2C+Inc.&amp;index=1&amp;md5=cfd69ef5c1086a0f09f9ca618962670e">Astria Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These results demonstrated robust overall reduction in the monthly attack rate (92% mean and 97% median). These results further support navenibart's favorable safety and tolerability profile, and potential every three- (Q3M) and every six-month (Q6M) dosing regimens.

ATXS

Astria Therapeutics Reports Initial Results From Target Enrollment Group In Ongoing ALPHA-SOLAR Long-Term Open-Label Trial Evaluating Navenibart In HAE Patients

Citizens Financial Expands Share Buyback Authorization To $1.5B, Company Cites Confidence In Growth Outlook

Jefferies analyst Roger Song downgrades CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) from Buy to Hold and lowers the price target from $7 to $5.

Downgrades

CVAC

Jefferies Downgrades CureVac to Hold, Lowers Price Target to $5

The 2025 Global Gender Gap Index, released by the World Economic Forum, shows that gender parity worldwide is still a distant fantasy, with 68.8% of the gap closed across 148 economies, an improvement of only 0.3 percentage points from last year.
What Happened: At the current pace, the report says, it will take 123 years to achieve full global gender parity.
Iceland continues to lead with a 92.6% score, holding the top spot for 16 years and remaining the only country above the 90% mark. The top 10 economies, which have achieved 80% parity, are dominated by European nations, including Finland, Norway, Sweden, Germany and Ireland.
The Health and Survival (96.2%) and Educational Attainment (95.1%) gaps are nearly closed. However, Economic Participation (61%) and Political Empowerment (22.9%) still lag far behind.
Political Empowerment has seen the most long-term improvement, increasing by 9 percentage points since 2006, but full parity is still 162 years away. Economic Participation has improved by 5.6 points in the same period, with 135 years to go at the current rate.
Regionally, Northern America leads in 2025 with 75.8% overall parity and ranks first in economic participation. However, its economic gender gap has barely improved since 2006.
See Also: <a href="https://www.benzinga.com/news/topics/25/06/45858225/track-star-shacarri-richardson-partners-with-reddit-co-founder-alexis-ohanian-to-build-multicity-athlos-track-empire">Track Star Sha&#8217;Carri Richardson Partners With Reddit Co-Founder Alexis Ohanian To Build Multicity Athlos Track Empire</a>
Why It Matters: Closing the gender gap is projected to add up to $7 trillion to the global economy, UN Women estimates.
According to an OECD paper on gender equality and economic growth, "closing labour force participation gaps could add 0.10 p.p. of additional economic growth per year, culminating in a 3.9% boost to GDP per capita by 2060."
This WEF report, released every year, measures access and opportunities essential for reaching full economic potential. It offers a benchmark to inform policy decisions and business strategies.
Speaking <a href="https://www.livemint.com/news/indias-gender-gap-widens-as-it-drops-to-131st-spot-in-global-gender-gap-index-2025-11749710477982.html">to</a> the Press Trust of India, Saadia Zahidi, Managing Director, World Economic Forum, said: "At a time of heightened global economic uncertainty and a low growth outlook combined with technological and demographic change, advancing gender parity represents a key force for economic renewal."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45920453/trumps-student-loan-policies-could-inflict-massive-economic-harm-for-americans-warns-expert-instead-of-helping-the-5-million-borrowers">Trump&#8217;s Student Loan Policies Could Inflict &#8216;Massive Economic Harm,&#8217; For Americans, Warns Expert: &#8216;Instead Of Helping The 5 million Borrowers&#8230;&#8217;</a></li>
</ul>
Photo courtesy: Drop of Light / Shutterstock.com

World Economic Forum Says Gender Equality Is 123 Years Away: UN Projects $7 Trillion Boost To Global Economy If Gap Closes

Canaccord Genuity analyst George Gianarikas initiates coverage on USA Rare Earth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) with a Buy rating and announces Price Target of $17.

Initiation

USAR

Canaccord Genuity Initiates Coverage On USA Rare Earth with Buy Rating, Announces Price Target of $17

Recent federal procurement filings indicate that U.S. Immigration and Customs Enforcement (ICE) is ramping up its use of blockchain analytics technology to bolster efforts against illegal activity involving cryptocurrency.
What Happened: ICE issued notices of intent to purchase additional investigative tools from TRM Labs and Chainalysis, according to <a href="https://fedscoop.com/ice-wants-more-blockchain-analytics-tech/">a</a> Fedscoop report.
These companies are among the leading providers of blockchain forensics software. The agency shared that it plans to sole-source from both companies due to a lack of feasible alternatives for their specialized services.
Additional purchases from Magnet Forensics and Volexity are also in the pipeline. These companies are already known vendors across federal law enforcement agencies like the FBI and IRS.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45919840/trump-says-i-like-tesla-as-feud-with-elon-musk-subsides-but-i-also-like-combustion-engines">Trump Says &#8216;I Like Tesla&#8217; As Feud With Elon Musk Subsides: &#8216;But I Also Like Combustion Engines&#8217;</a>
Why It Matters: Blockchain transactions are visible on public ledgers, but they often obscure user identities. As criminal organizations continue to adopt digital currencies to evade detection, analytics platforms are becoming crucial for tracing hidden financial trails.
According to TRM Labs' Ari Redbord, these tools are aiding agencies to track cryptocurrency use in terrorism financing, human trafficking and cross-border smuggling. He highlighted that their systems can trace transactions even when bad actors use complex tactics to disguise activity.
ICE is stepping up its implementation of advanced technology across a variety of domains. Earlier this year, it signed a $29.8 million contract with Peter Thiel, the co-founder of Palantir Technologies Inc. (PLTR), to enhance its immigration enforcement tools.
The agency is currently making headlines for triggering <a href="https://www.benzinga.com/news/politics/25/06/45900294/trump-deploys-marines-to-la-with-authority-to-detain-civilians-california-challenges-military-involvement-in-immigration-enforcement">widespread protests</a> in Los Angeles against its <a href="https://www.benzinga.com/markets/equities/25/06/45854643/home-depot-targeted-in-immigration-raids-amid-la-protests-threatening-customer-traffic">targeted immigration raids</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45920411/trumps-approval-rating-hits-second-term-low-amid-ukraine-and-israel-conflicts">Trump&#8217;s Approval Rating Hits Second-Term Low Amid Ukraine And Israel Conflicts</a></li>
</ul>
Photo courtesy: chrisdorney / Shutterstock.com

Politics

PLTR

ICE Looks To Ramp Up Blockchain Surveillance Capabilities With New Purchases From TRM Labs, Chainalysis: Report

Keybanc analyst Steve Barger upgrades Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) from Sector Weight to Overweight and announces $21 price target.

Keybanc Upgrades Myers Indus to Overweight, Announces $21 Price Target

In response to Israel&#8217;s recent strikes on Iranian nuclear sites, President Donald Trump issued a stern warning to Iran, urging the country to negotiate or face dire consequences.
What Happened: Trump, via his Truth Social account on Friday, criticized Iran for failing to secure a nuclear deal despite multiple opportunities. He highlighted the military prowess of the U.S. and Israel, emphasizing their advanced weaponry and preparedness.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="606" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13063653/image-218.png" alt="" class="wp-image-948795" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13063653/image-218.png 606w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/13063653/image-218-300x262.png 300w" sizes="(max-width: 606px) 100vw, 606px" /></figure>
Trump, referring to Israel&#8217;s &#8220;Rising Lion&#8221; strikes that damaged Natanz and eliminated Revolutionary Guard leaders, including Chief Hossein Salami, warned of severe repercussions.&nbsp;He stated that Iranian hardliners, now &#8220;all DEAD,&#8221; had underestimated the response. &nbsp;Trump urged Iran to swiftly engage in negotiations to prevent further &#8220;slaughter&#8221; and &#8220;brutal&#8221; planned attacks, cautioning of the potential collapse of the &#8220;Iranian Empire.&#8221;
The President&#8217;s post corresponds with reports of rising tensions in the Middle East and the cancellation of U.S.-Iran talks. His message, while advocating for diplomacy, also threatens the use of overwhelming force, sparking fears of a broader conflict in the region.
SEE ALSO:&nbsp;<a href="https://benzinga.com/crypto/25/06/45897204/gamestop-themed-crypto-skyrockets-over-500-after-retailer-announces-1-75-billion-investment-plan" target="_blank" rel="noreferrer noopener">GameStop-Themed Crypto Skyrockets Over 500% After Retailer Announces $1.75 Billion Investment Plan &#8211; Benzinga</a>
Why It Matters: The Trump administration had&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/45919250/trump-administration-distances-us-from-israels-strikes-on-iran-we-are-not-involved-says-marco-rubio">distanced itself </a>from Israel&#8217;s recent military actions against Iran, a move that was expected to complicate Trump&#8217;s efforts to negotiate a nuclear deal with Tehran. The U.S. was preparing for another round of talks on Iran&#8217;s uranium enrichment program, scheduled for Sunday.
Earlier, Trump had made a significant diplomatic gesture towards Iran, expressing hope for improved relations in the Middle East. This came as he lauded the transformative efforts of Saudi Arabia, Qatar, and the United Arab Emirates in turning their capitals into thriving commercial centers. Trump&#8217;s softer tone towards Iran was seen as an indication of his administration&#8217;s&nbsp;willingness to seek a <a href="https://www.benzinga.com/25/05/45395894/trump-makes-peace-gesture-at-iran-amid-middle-east-optimism-willing-to-end-past-conflicts-and-forge-new-partnerships">nuclear deal</a> with Tehran.
The recent events have had a significant impact on the markets, with U.S. stocks likely to open lower following Israel&#8217;s strikes on Iran. The geopolitical risks have also offered an upside for the dollar, raising concerns about a further rise in tensions in the Middle East and their impact on supply routes.
Meanwhile, defense stocks like Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), and General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) <a href="https://www.benzinga.com/markets/equities/25/06/45921574/lockheed-martin-rtx-general-dynamics-and-other-defense-stocks-rise-in-friday-pre-market-whats-going-on">climbed higher </a>in Friday&#8217;s pre-market trading session amid escalating tensions in the Middle East.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/tech/25/06/45920468/barack-obama-once-told-airbnb-ceo-brian-chesky-not-to-lead-like-a-self-driving-car-heres-what-former" target="_blank" rel="noreferrer noopener">Barack Obama Once Told Airbnb CEO Brian Chesky Not To Lead Like A &#8216;Self-Driving Car:&#8217; Here&#8217;s What Former President Meant</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Trump Issues Stark Warning To Iran To 'Make A Deal' After Israel's Strikes On Nuclear Sites: 'Just Do It Before It's Too Late'

IONR

Trading Halt: Halt status updated at 6:55:00 AM ET: Quotation Resumption: News and Resumption Times

Needham analyst Mike Matson reiterates Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) with a Buy and maintains $48 price target.

Reiteration

ESTA

Needham Reiterates Buy on Establishment Labs Hldgs, Maintains $48 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $73 price target.

Telsey Advisory Group Maintains Outperform on Kroger, Maintains $73 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Outperform and maintains $255 price target.

Telsey Advisory Group Maintains Outperform on RH, Maintains $255 Price Target

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Buy and maintains $35 price target.

Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $35 Price Target

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1)
 &nbsp;

Merck & Company Says FDA Has Approved KEYTRUDA (pembrolizumab) For PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma As Neoadjuvant Treatment, Continued As Adjuvant Treatment Combined With Radiotherapy With Or Without Cisplatin Then As A Single Agent

Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of BMF-500 in adults with relapsed or refractory ("R/R") acute leukemia ("AL"). The results will be presented in a poster presentation at the European Hematology Association ("EHA") 2025 Congress in Milan, Italy.
The presentation by Dr. Farhad Ravandi of The University of Texas MD Anderson Cancer Center will highlight emerging safety, pharmacokinetics/pharmacodynamics, and early clinical activity data for BMF-500, a highly selective covalent FMS-like tyrosine kinase 3 ("FLT3") inhibitor, in heavily pretreated patients with R/R AL.
Key Results from the EHA 2025 Poster Presentation 27 patients were enrolled across two study arms, Arm A (no CYP3A4 inhibitor; n=10) and Arm B (CYP3A4 inhibitor; n=17). All patients had R/R AL, with a median of 4 prior lines of therapy. 18 of the 27 patients were FLT3 mutations ("FLT3m") while the other 9 patients had FLT3 wild-type AL. Frequent co-mutations included WT1, TP53, IDH1/2, and NRAS. All 18 FLT3m patients had failed gilteritinib in the R/R setting and 9 of the 18 had received at least two FLT3 inhibitors prior to study entry. 26 of 27 (96%) enrolled patients had also received and failed the BCL2 inhibitor venetoclax. Key findings include:
Clinical Activity Observed:
<ul>
<li>9 of 11 efficacy-evaluable FLT3m patients, defined as all patients enrolled who received at least one dose and had at least one disease assessment, showed bone marrow (BM) blast reduction; 5 of 11 achieved &gt;50% BM blast reduction.</li>
<li>1 FLT3m patient achieved complete remission with incomplete hematologic recovery (CRi), sustained for 6 cycles.</li>
<li>1 FLT3m patient achieved morphologic leukemia-free state (MLFS); response is ongoing.</li>
<li>1 FLT3m patient met all criteria for partial response (PR) except platelet recovery; categorized as near PR.</li>
<li>2 of 4 efficacy-evaluable FLT3 wild-type patients achieved durable disease control ≥120 days, with treatment ongoing for one patient.</li>
<li>Additional clinical improvements include reductions in peripheral blasts, transfusion dependency, and frequency of hydroxyurea use.</li>
</ul>
Pharmacokinetics/Pharmacodynamics:
<ul>
<li>FLT3 inhibition correlated with BMF-500 systemic exposures.</li>
<li>Bone marrow and plasma concentrations of BMF-500 and its metabolites were comparable, suggesting good compartmental penetration.</li>
</ul>
Survival:
<ul>
<li>Median overall survival (mOS) among all treated FLT3m patients (n=18) was 3.8 months (Arm A) and 3.5 months (Arm B) during dose escalation.</li>
<li>For the efficacy-evaluable FLT3m patients (n=12), the mOS for Arms A and B was 3.8 and 3.6 months, respectively during dose escalation.</li>
<li>These survival durations compare favorably to historical mOS of 2.1 months in patients with R/R FLT3m acute myeloid leukemia ("AML") post-failure with both gilteritinib and venetoclax.&nbsp;</li>
</ul>
Ongoing Dose Escalation:
<ul>
<li>Dose escalation continues at 200 mg BID (Arm A) and 75 mg BID (Arm B).</li>
<li>Based on observed activity and tolerability, further evaluation is underway to determine optimal biologic dose ("OBD") and recommended Phase II dose ("RP2D").</li>
</ul>
Safety and Tolerability
<ul>
<li>BMF-500 was generally well-tolerated across dose levels.</li>
<li>No dose-limiting toxicities (DLTs), QT prolongation, or discontinuations due to treatment-related adverse events were reported.</li>
<li>Escalation is ongoing without safety restrictions.</li>
</ul>
Following completion of the COVALENT-103 dose escalation phase in R/R AL patients with FLT3m, Biomea plans to conclude its internal development of BMF-500 in oncology and is actively exploring strategic partnerships to advance the program.

BMEA

Biomea Fusion Presents Updated Preliminary Clinical Data From Ongoing Phase I COVALENT-103 Trial Of BMF-500 In Adults With R/R Acute Leukemia, At EHA 2025 Congress

WIIM

SHEL

Shraes of energy stocks are trading higher following Israel's strikes on Iran, which have raised oil prices amid potential disruptions in production.

Biotech

Large Cap

Health Care

Contracts

General

AstraZeneca Has Entered A Strategic Research Collaboration With Shijiazhuang City-based CSPC Pharmaceuticals For Oral Candidates To Treat Diseases Across Multiple Indications, CSPC Will Receive An Upfront Payment Of $110M, And Is Also Eligible To Receive Up To $1.62B In Potential Development Milestone Payments And Up To $3.6B In Sales Milestone Payments, Plus Potential Single-digit Sales Based Royalties.

JBLU

Shares of airline stocks are trading lower following Israel's strikes on Iran, which have raised fuel prices and could cloud the travel demand outlook. The recent crash of an Air India flight could also be pressuring the sector.

GPUS

Hyperscale Data Projects $41M Annual Bitcoin Mining Run Rate Starting July 2025 With 19,200 Miners Across US Sites

Press Releases

Boston Omaha Corporation Announces Adoption of $20 Million Class A Common Stock Repurchase Program

Boston Omaha Broadband Promotes J. Max Meisinger as President and Chief Executive Officer of Broadband Division

Fiber Fast Homes Appoints New CEO to Further Fiber to the Home Internet Adoption Collaborating with Developers and Builders

Boston Omaha Corporation Announces Second Quarter 2024 Financial Results

Boston Omaha Corporation Announces Third Quarter 2024 Financial Results

Boston Omaha Corporation Announces Bradford Briner's Resignation from Boston Omaha's Board of Directors Following His Election as Treasurer of the State of North Carolina

Comments

Boston Omaha

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO